Abstract
In this retrospective analysis of 443 Alzheimer disease (AD) patients from a 30-week tacrine trial, change in Alzheimer's Disease Assessment Scale score from baseline to final value was significantly associated with a total serum cholesterol/APOE genotype interaction. Disease progression in the no-APOE epsilon4 allele/high-cholesterol subgroup was greater than in the normal-cholesterol subgroups with or without epsilon4. Cholesterol levels and APOE genotype may interact to affect AD progression. The results are consistent with preclinical data on cholesterol's effects in AD.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Alzheimer Disease / blood
-
Alzheimer Disease / complications
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / genetics*
-
Apolipoprotein E4
-
Apolipoproteins E / genetics*
-
Cholesterol / blood*
-
Disease Progression
-
Double-Blind Method
-
Female
-
Genetic Predisposition to Disease
-
Genotype
-
Humans
-
Hyperlipoproteinemia Type II / blood
-
Hyperlipoproteinemia Type II / complications
-
Hyperlipoproteinemia Type II / genetics*
-
Male
-
Middle Aged
-
Neuroprotective Agents / therapeutic use
-
Retrospective Studies
-
Severity of Illness Index
-
Tacrine / therapeutic use
Substances
-
Apolipoprotein E4
-
Apolipoproteins E
-
Neuroprotective Agents
-
Tacrine
-
Cholesterol